scispace - formally typeset
Journal ArticleDOI

Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence.

Reads0
Chats0
TLDR
Polytherapy was used by one-third of patients initially and at one year, antidepressant use was highly prevalent initially and later, but lack of treatment was prevalent at one Year, and plausible clinical and treatment factors were associated with sustained mood stabilizer adherence.
Abstract
Objective: Because treatments for bipolar disorder include a growing number of psychotropic agents, the authors evaluated psychotropic polytherapy and adherence to treatment among U.S. patients with bipolar disorder. Methods: National health plan claims data (2000–2004) were used to identify patients diagnosed as having bipolar disorder who had continuous benefits and had not been prescribed medication for bipolar disorder for six months or more. The study compared drugs dispensed to these patients initially and at one year and characterized patients who were adherent to mood-stabilizers. Results: A total of 7,406 patients had a bipolar disorder: bipolar I (55%), bipolar II (15%), or bipolar disorder not otherwise specified (30%). Women represented 57% of the sample; mean±SD age was 35.4±12.4 years. Initial prescription fills involved one psychotropic agent in 67% of patients, and two or more psychotropics (polytherapy) in 33%. Initial prescription drug selections involved: antidepressants > anticonvulsants ≥ antipsychotics > sedatives > lithium; initial mood stabilizer use ranked: valproate > lithium > carbamazepine or oxcarbazepine > lamotrigine; antipsychotics ranked: olanzapine > quetiapine ≥ risperidone > ziprasidone > aripiprazole > clozapine. Rankings were similar at one year, when only 31% of patients received monotherapy (a 2.2-fold decline), 32% received polytherapy, and 37% received no psychotropics. Initially patients received 1.42 psychotropic drugs per person; at one year, patients received 175, and at both times polytherapy was less likely with lithium than with anticonvulsants. In multivariate modeling, one-year mood stabilizer use was greater with the following: older age, type of mood stabilizer (lamotrigine > valproate > carbamazepine or oxcarbazepine > lithium) and was associated with more psychiatric office and emergency visits, clinician type (more common with psychiatrists than with primary care physicians), and nonuse of off-label anticonvulsants. Conclusions: Polytherapy was used by one-third of patients initially and at one year, antidepressant use was highly prevalent initially and later, but lack of treatment was prevalent at one year. Plausible clinical and treatment factors were associated with sustained mood stabilizer adherence. (Psychiatric Services 59:1175–1183, 2008)

read more

Citations
More filters
Journal ArticleDOI

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide.

TL;DR: These data do not provide evidence for an association of acute pancreatitis among initiators of exenatide or sitagliptin compared to met/gly initiators and are limited by the data available in an administrative, healthcare database.
Journal ArticleDOI

Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood

TL;DR: Both childhood onset and treatment delay were associated with a persistently more adverse course of illness rated prospectively in adults, converging with other evidence that onset of bipolar disorder in childhood is common and often associated with extraordinarily long delays to first pharmacologic treatment.
Journal ArticleDOI

The prevalence and burden of bipolar depression.

TL;DR: The findings support the predominance of depressive symptoms compared with mood elevation/mixed symptoms in the course of bipolar illness, and thus an overall greater burden in terms of economic costs, functioning, caregiver burden, and suicide.
Journal ArticleDOI

Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks

TL;DR: Long‐term antidepressant treatment for depression in bipolar disorder (BPD) patients is highly prevalent, but its benefits and risks remain uncertain, encouraging this meta‐analysis of available research.
References
More filters
Journal ArticleDOI

A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation☆

TL;DR: The method of classifying comorbidity provides a simple, readily applicable and valid method of estimating risk of death fromComorbid disease for use in longitudinal studies and further work in larger populations is still required to refine the approach.
Journal ArticleDOI

Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases

TL;DR: It is concluded that the adapted comorbidity index will be useful in studies of disease outcome and resource use employing administrative databases.
Journal ArticleDOI

The long-term natural history of the weekly symptomatic status of bipolar I disorder.

TL;DR: Overall, the symptomatic structure is primarily depressive rather than manic, and subsyndromal and minor affective symptoms predominate, and the longitudinal weekly symptomatic course of BP-I is chronic.
Journal ArticleDOI

Mortality of patients with mood disorders: follow-up over 34–38 years

TL;DR: Men and women hospitalised for affective disorders have elevated mortality rates from suicide and circulatory disorders and long term medication treatment lowers the suicide rates, despite the fact that it was the more severely ill who were treated.
Journal ArticleDOI

Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review.

TL;DR: Risks of completed and attempted suicide were consistently lower, by approximately 80%, during treatment of bipolar and other major affective disorder patients with lithium for an average of 18 months, and these benefits were sustained in randomized as well as open clinical trials.
Related Papers (5)